

Will public-private partnerships take the leap into open science?

Pierre Meulien, Executive Director of the Innovative Medicines Initiative (IMI)



 **BIO**
International
Convention

— ♥ ▲ ▼ —
25 YEARS
OF **Bio** INNOVATION


IMI – Europe's partnership for health

IMI1: 2008-2013

€2 bn (\$2.4 bn)
59 projects

IMI2: 2014-2020

€3.3 bn (\$4 bn)
More ambitious
More open
Greater scope




IMI – Europe’s partnership for health

IMI2 Strategic Research Agenda

- Antimicrobial resistance
- Osteoarthritis
- Cardiovascular diseases
- Diabetes
- Neurodegenerative diseases
- Psychiatric diseases
- Respiratory diseases
- Immune-mediated diseases
- Ageing-associated diseases
- Cancer
- Rare/Orphan Diseases
- Vaccines

Aligned with WHO priorities

Over 11 500 researchers from an international, cross-sector community



Open Innovation vs. Open Science

Open Innovation


- Model of collaboration
 - “... combines internal and external ideas into architectures and systems whose requirements are defined by a business model ...”
- Chesbrough (2003)
- Inherent to IMI

Open Science

- Practice of science to remove barriers for sharing and accessing knowledge, data, etc.
- Also an EU political objective translated into EU policy

Making Open Science a Reality

Several components which may be independent from each other



Our Panelists

- **Carlo Incerti**

Head of Global Medical Affairs, Sanofi Genzyme

- **David Wholley**

Senior Vice-President, Research Partnerships, Foundation for the National Institutes of Health

- **Shyam Bishen**

US Regional Director, Life Sciences Partnerships Global Health, Bill and Melinda Gates Foundation

- **Nikolay Savchuk**

Managing Director, Torrey Pines Investment